James Nishiyama Finucane is Co-Founder and CTO at Mirae, an AI-driven continuous care platform transforming how autoimmune diseases like inflammatory bowel disease are managed through real-time patient data and clinical intelligence.

James studied Mathematics at Connecticut College (2009-2013) and co-founded mPharma in 2012, where he served as CTO and helped build affordable, accessible health systems across Africa, earning recognition on the Forbes 30 Under 30 list.

A serial healthtech entrepreneur and technologist, James brings a rare combination of deep engineering expertise and a mission-driven focus on expanding access to quality care for underserved patient populations globally.

Prior to Mirae, James served as Head of Remote Engineering at GitStartHQ (YC S19) and Co-Founder and CTO of EQ Creative Markets, building a track record across high-growth, venture-backed technology companies.

Mirae launched with $5.4M in seed funding led by Oxford Science Enterprises and is already deployed with a leading U.S. health system, bringing Oxford-rooted AI research directly into clinical workflows for IBD patients.